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Background: The NAD-dependent protein deacetylase SIRT1 has a wide range of different targets, which may be
regulated either directly through deacetylation and thus potentially altering their activity or localization or indirectly
by deacetylation of histones, which in turn alters their transcription rate and availability. SIRT1 is therefore involved
in the regulation of many different and fundamental cellular processes such as apoptosis, metabolism, differentiation
and cell cycle arrest. It is also involved in the regulation of resistance of cells against oxidative stress and longevity
under conditions of caloric restriction. Even though the targets and role of SIRT1 have been studied quite intensively,
only little is known about the mechanisms affecting SIRT1 transcriptional regulation. The nuclear factor NFκB is a
well-studied and widely known transcription factor, which is involved in the regulation of many important cellular
activities. The regulation of NFκB by SIRT1 has been reported recently, but it is, however, still unknown whether a
feedback mechanism affects the regulation of SIRT1 too, particularly in view of the fact that putative NFκB binding sites
within the SIRT1 promoter suggest just that.
Results: In the study presented herein we show that there is activation of the SIRT1 promoter by overexpression of
different NFκB subunits. Direct binding of NFκB to the SIRT1 promoter can be demonstrated by an electrophoretic
mobility shift assay. Further investigations indicated enhanced expression of SIRT1 on the mRNA levels in cells
overexpressing NFκB. A functional assay showed that acetylation of one of the main target proteins of SIRT1 is reduced
in these cells.
Conclusions: These finding together indicate SIRT1 expression to be regulated in a positive feedback loop by NFκB.
The putative binding sites for NFκB found within the SIRT1 promoter appears to be functional and several NFκB
subunits are able to enhance the expression of SIRT1 if they are overexpressed.
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The regulation of activity, cellular localization and stabil-
ity of nearly all proteins depends on post-transcriptional
and/or post-translational modifications. Such modifica-
tions are being carried out by a diversity of chemical re-
actions including (de)phosphorylation, (de)acetylation or
ubiquitination and many others. These highly dynamic
regulatory processes are controlled and driven by antag-
onizing enzymes and allow cells to react to environmental* Correspondence: mahlknecht@gmx.de
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reproduction in any medium, provided the orchanges and to communicate with each other. Histone
deacetylases (HDACs) are one such group of enzymes.
HDACs are ubiquitous and catalyze the removal of acetyl
groups from both histones and non-histone proteins. The
most obvious and best examined role of HDACs is their
effect on the constitution and maintenance of chromo-
somal structure as well as the regulation of global gene ex-
pression through modification of the so called histone
code and alteration of the accessibility of genes for tran-
scription factors [1]. However, apart from their role as
superordinative gene regulators and their role in the con-
trol of chromatin structure, some proteins of this family
are associated with the distinct regulation of single target
proteins, which may specifically be deacetylated [2].
Histone deacetylases are divided into four different
classes: three groups of classical HDACs known as class I,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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referred to as the ‘sirtuins’ [3]. The sirtuins differ from
the other classes of HDACs based on their dependence on
the presence of the coenzyme NAD+ [4]. Seven human
sirtuins, which are homologs of the yeast silent informa-
tion regulator 2 (SIR2) protein, have been reported so far.
SIR2 is responsible for the transcriptional silencing of
silent mating loci, telomeres and ribosomal DNA in yeast.
It also suppresses the recombination of rDNA and thereby
lowers the formation of toxic extrachromosomal rDNA
rings, which extends lifespan in yeast cells dramatically
[5]. Yeast SIR2 or mammalian sirtuin overexpression goes
along with the global deacetylation of histones [6]. Most
of the gene silencing effects that are being associated with
sirtuin activity depend on the deacetylation of histone H4
lysine 16 (H4K16) [7] and/or histone H3 lysines 9, 14 or 18
(H3K9, H3K14, H3K18) [8]. Depending on the presence of
NAD+, the sirtuins are biological sensors for the cellular
energetic and oxidative status. Thus, high levels of NAD+
go along with high sirtuins activity [9].
The human deacetylase sirtuin1 (SIRT1) shares the
highest degree of homology of all mammalian sirtuins
with the yeast protein SIR2. SIRT1 localizes predominantly
to the cell nucleus [10] and deacetylates both histones
(preferably H4K16) and non-histone proteins. SIRT1 antag-
onizes the histone acetyltransferase p300 [11], which acet-
ylates all histones and some non-histone proteins such as
p53 and FOXO3a. SIRT1 is involved in a number of cellu-
lar regulation mechanisms affecting cellular lifespan, stress
resistance, apoptosis and cell metabolism [12]. The pro-
longation of cellular lifespan under conditions of caloric
restriction has been known for quite some time. It has
been described for a number of very different organisms
ranging from yeast [13] to nematodes [14] to mammals
[15,16] and has been reported to be associated with SIRT1.
Caloric restriction causes an increase in the production
of NAD+ and goes along with increased levels of SIRT1
mRNA [13,16] as well as with increased SIRT1 activity
[17]. The positive influence of SIRT1 on longevity in mam-
mals has been reported to depend on increased stress
resistance and reduced apoptosis. In addition to the modi-
fication of histone proteins, SIRT1 also carries the ability
to inactivate a number of non-histone proteins by de-
acetylation. One of the most prominent examples for this
mechanism is the deacetylation of tumor suppressor pro-
tein p53. The transcription factor p53 triggers apoptosis
in the case of DNA damage or oxidative stress and plays
a key role in cellular defense against the development of
malignant transformation [18]. The inactivation of p53
by SIRT1 may retard apoptosis and render cells more re-
sistant to oxidative stress [19,20]. On the other hand,
overexpression of SIRT1 may also promote carcinogenesis
because of its inhibitory effect on apoptosis and cell cycle
arrest. The forkhead proteins constitute another group ofproteins that is also involved in the regulation of apoptosis,
stress resistance and metabolism; these proteins are re-
ported to be regulated by SIRT1 [21].
Another protein that may be deacetylated by SIRT1 is
the nuclear factor NF-kappa-B (NFκB) [22-24]. NFκB is
a ubiquitously distributed transcription factor that con-
trols gene expression of many target genes, thereby af-
fecting important cellular functions such as cell cycle,
angiogenesis, adhesion and apoptosis [25]. NFκB is being
constituted by homo- and heterodimers of different NFκB/
Rel-proteins, which all share a highly conserved DNA
binding/dimerization domain called ‘Rel homology (RH)
domain’ [26]. NFκB/Rel proteins can be divided into two
classes. Members of the first class are coded by the genes
NFKB1 and NFKB2 both of them normally being tran-
scribed as long isoforms called NFκB-p105 and NFκB-
p100, which are inactive as long as they have inhibiting
C-terminal domains. The shorter active forms of this
class, the NFκB-p50 (derived from p105) and NFκB-p52
(derived from p100) are produced by arrested transla-
tion or partial proteolysis of the longer forms. The sub-
unit NFκB-p49 is another isoform that can be generated
from an alternatively spliced transcript of p100. It is
reported to be involved in the activation of the HIV en-
hancer [27]. The second class contains the proteins c-Rel,
RelA (also called NFκB-p65) and RelB, which may activate
gene expression in homodimers as well as in heterodimers
[28]. The most prevalent and best studied dimer is the
heterodimer consisting of the p65 and p50 protein. NFκB
is constitutively transcribed in many different cell types,
but it remains inactive because the dimers are bound to
inhibitory proteins of the IκB family, which mask their nu-
clear translocation signal and consequently go along with
their localization in the cell cytoplasm. In response to
diverse stimuli IκB proteins are phosphorylated by IκB
kinase (IKK) which triggers their ubiquitination and thus
their degradation by the proteasome machinery. NFκB is
subsequently translocated to the nucleus were it interacts
with promoters, thus activating the expression of specific
target genes [29].
Generally speaking, alterations of SIRT1 gene expres-
sion are associated with changes in cell metabolism, dif-
ferentiation, proliferation and many other fundamental
cell features and may therefore affect numerous diseases
such as diabetes, cancer or arteriosclerosis. Therefore,
regulation of SIRT1 gene expression at the promoter
level is of great interest in order to further elucidate our
understanding of the molecular mechanisms that involve
SIRT1 in both health and disease. The goal of the study
presented herein consists in the further elucidation of
the interplay of the transcription factor NFκB, in the re-
ciprocal regulation with SIRT1, taking into consideration
possible feedback mechanisms in the regulation of these
two proteins.
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Human SIRT1 gene promoter analysis
Alterations in the SIRT1 expression rate are associated
with changes in cell metabolism, differentiation, prolifer-
ation and many other fundamental cell features and
affect many diseases such as diabetes, cancer or arterio-
sclerosis. But at present little information is available on
the molecular mechanisms regulating SIRT1 at the pro-
moter level. In order to further elucidate the regulation
of SIRT1 at the promoter level, a search for putative
transcription factor binding sites was carried out using
the online tool MOTIF Search (http://motif.genome.jp).
The search was based on the alignment with the tran-
scription factor database TRANSFAC. Among others, we
found the SIRT1 promoter to contain several putative
NFκB binding sites. NFκB is a transcription factor that is
involved in apoptosis, the regulation of cellular stress,
and numerous immunological functions. The NFκB con-
sensus sequence GGGAMTTYCC with M and Y being
exchangeable bases was found with minor variations in
three positions of the SIRT1 promoter. The three men-
tioned positions are located at the promoter base-pair
positions 1,168 to 1,177 bp, 1,441 to 1,450 bp and 1,838
to 1,847 bp. In accordance with our in silico analyses the
latter two NFκB potential binding sites appeared to be
specific for the NFκB subunit p65. This suggests that
Sirt1 expression could potentially be regulated by NFκB.Figure 1 SIRT1-promoter activation after transfection of NFκB subuni
cotransfected with expression vectors for different NFκB subunits in HEK-29
protein concentration of cell extracts was used to normalize the results. To
control) was measured after transfection of the SIRT1 reporter plasmid withNFκB regulates the SIRT1 promoter
In order to further investigate whether NFκB was involved
in the regulation of SIRT1 at the promoter level, a lucifer-
ase reporter plasmid was generated, which contained a
2,228-bp-long fragment of the SIRT1 promoter sequence.
This construct was cotransfected in HEK293T cells to-
gether with different combinations of expression vectors
of the NFκB subunits p49, p50 or p65. Luciferase activity
of cell extracts was measured 24 hours after transfection
and normalized to the protein content of the cell extracts.
Figure 1 plots the results of three independent measure-
ments of luciferase activity relative to the constitutive
activity. The constitutive activity was determined by trans-
fection of the reporter plasmid without cotransfection of
any expression plasmids for NFκB. These results show
clearly that the Sirt1 promoter is activated in general by
overexpression of NFκB. Statistical P values indicated in
the diagram were calculated using a Mann-Whitney U
Test and show significance for the difference of each NFκB
subunit combination versus control (P ≤0.05). The differ-
ent combinations of NFκB subunits we transfected in
order to determine the effects of the different homo- and
heterodimers of NFκB did not show significant differences
among each other (P >0.1).
Our experiments showed overexpression of NFκB p50
subunit or NFκB p65 subunit alone to increase SIRT1
promoter activity by an average of 8.6-foldand 7.3-fold.ts. Reporter plasmids containing the SIRT1 promoter were
3 T cells. Luciferase reporter gene assay was done after 24 hours and
calculate relative values constitutive luciferase intensity (named
out NFκB expression plasmids. n = 3. *P ≤0.05 versus control group.
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combination was identified to have an activating effect on
the SIRT1 promoter with an average of about 7.9-fold,
which is very similar to the effects of overexpression of
the single subunits. The heterodimer p50/p65 represents
the most common and best examined variant of NFκB,
which makes these results the most interesting. The over-
expression of p49 together with p65 also showed SIRT1
promoter activation. The activating effect of this combi-
nation seemed to be lower with an average of only 4.2-
fold, but the difference to the other subunit combinations
is not significant. Overexpression of all three subunits to-
gether goes along with a seven-fold activation of the SIRT1
promoter, which is similar to the other results. Transfec-
tion of the empty reporter plasmid (without Sirt1 pro-
moter) was used as negative control and did not show any
luciferase activity.
NFκB regulates SIRT1 expression
In order to examine whether the effects of promoter ac-
tivation through overexpression of NFκB in fact had influ-
ence on the SIRT1 expression levels, RNA from HEK293T
cells was extracted after transient transfection with the
NFκB expression constructs. In quantitative real-time PCR
we observed a 1.8 to 3-fold upregulation for SIRT1 at the
mRNA level (Figure 2) in response to NFκB overex-
pression for nearly all combinations of NFκB subunits ex-
cept in the combination of p50 with p65, which had only
minor effects on SIRT1mRNA expression levels in this ex-
periment. The little effect of the overexpression of p50 inFigure 2 SIRT1 expression on mRNA level. HEK-293 T cells were transfec
24 hours later. Cells transfected with empty vector were used as reference
measured by real-time-PCR.combination with p65 on the mRNA level, does not fit
with the remarkable promoter activating effects seen for
this combination in the luciferase assay. A possible explan-
ation may be based on the fact that the p50/p65 dimer is
the most common dimer of NFκB, which has numerous
physiological functions in the cell. Therefore, other regu-
lating mechanisms may also be activated that could affect
SIRT1 expression.
Functional assay of SIRT1 activity
A functional assay was carried out not only to investi-
gate the levels of SIRT1 expression but also the effects
of NFκB on cell metabolism and other proteins in asso-
ciation with SIRT1. In order to prove relevant changes
in SIRT1 activity after NFκB overexpression we investi-
gated the acetylation status of histone H4 lysine residue
16 (H4K16), which is targeted and deacetylated by SIRT1.
We isolated the histone fraction of cells after transfec-
tion with defined NFκB subunits and analyzed the his-
tone H4 acetylation status by western blot technique.
Figure 3A shows a remarkable decrease of acetylated
H4K16 in cells overexpressing NFκB. For quantification of
the results, blots were scanned and acetylated histone H4
was normalized to the amount of total histone H4 on the
same blot. To be sure, that the effects are not due to the
circumstances of cell culture or transfection in general,
which may change acetylation status of histones because it
induces lots of metabolical reactions and stress, we com-
pared the results of cells transfected with NFκB vector
with those transfected with an empty vector. Figure 3Bted with expression plasmids of different NFkB subunits and harvested





Figure 3 Histone acetylation status in response to SIRT1 activity. Cells were transfected with expression vectors for different NFκB subunits.
Expression vector for SIRT1 was used as a positive control. Histones were isolated after 24 hours and acetylation status was assessed by western blot.
Transfection with empty vector was used as a reference control. (A) Detection was carried out with an antibody specific for acetylated histone H4K16 and
with another antibody binding to histone H4 independently of the acetylation status (total H4). (B) Detection films of blots were scanned and quantified
in silico. Values of H4K16 were normalized to total H4 and fold changes relative to control were calculated. n = 3. *P >0.05 versus empty vector.
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combinations resulted in a significant reduction of the
relative amount of acetylated histone H4. The amount
of reduction in cells overexpressing two or more NFκB
subunits was similar to the reduction caused by direct
overexpression of SIRT1. In cells overexpressing only one
subunit of NFκB protein the effects are less but still de-
tectable. These results suggest that overexpression of
NFκB has activating effects on the deacetylation of histone
H4, which could be mediated through induction of SIRT1
expression, particularly when two or three of the NFκB
subunits are overexpressed, thus allowing for a formation
of heterodimers.Binding of NFκB to SIRT1 promoter
To investigate the role of different putative NFκB binding
sites, truncations of the SIRT1 promoter were generated
(Figure 4). The 2,228 bp and 1,148 bp SIRT1 promoter
fragments contained all three putative NFκB binding sites;
fragments with length ranging from 1,026 bp, to 921 bp
and 887 bp in length contained only two NFκB binding
sites and the 668 bp fragment contained only one NFκB
binding site.
An electrophoretic mobility shift assay was done to
measure the binding of NFκB to the promoter and to in-
vestigate the relation of the three potential binding sites.
In order to induce NFκB expression, cells were treated
Figure 4 Sirt1 promoter truncations. Schematic illustration of Sirt1 promoter fragments used for electrophoretic mobility shift assay. The
positions of NFkB binding sequences are marked by arrows.
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treated cells were isolated and incubated with biotin la-
beled DNA fragments. The reaction mixture was resolved
on a 6% non-denaturing polyacrylamide gel. For all of the
tested promoter fragments signals were detected (Figure 5),
which proves binding of NFκB. The putative binding site
contained in the short fragment is likely to be involved in
the NFκB binding of the promoter, but because all of the
fragments showed a signal, it is not possible to decide
whether the binding is mediated solely by this single site
or whether all three sites are involved. Nuclear extracts
from untreated cells were used as negative controls. NFκB
oligonucleotides were used as a positive control to prove
induction of NFκB expression by TNFα and to compare
the position of the bands on the blot. The positive control
showed a signal that was much stronger than the labeled
promoter fragments. This may be caused by the high sen-
sitivity of the control, which also could explain the signal
seen for the NFκB oligonucleotides when incubated with
untreated cells.
Conclusions
NFκB is a transcription factor that can be found in nearly
all cell types. NFκB regulates immune reactions and isFigure 5 Binding of NFκB to DNA fragments of truncated SIRT1 prom
Nuclear extracts of TNFα-treated and untreated control cells were incubate
and were analyzed by electrophoretic mobility shift assay. An NFκΒ oligonuinvolved in the regulation of cellular stress resistance and
apoptosis. Also, it has recently been shown that the NFκB
binding sequence is a gene regulatory motif that is most
essentially involved in the regulation of cellular aging.
SIRT1 is a highly conserved protein involved in many cel-
lular processes in both health and disease. It has been
reported to be involved in the extension of cellular life
span under conditions of caloric restriction in many spe-
cies. Its positive influence on stress resistance of cells is
widely known and its activation prevents apoptosis and
cell cycle arrest. Since both proteins, SIRT1 as well as
NFκB, are involved in the regulation of immune response,
cellular stress, and aging, a regulatory connection between
them would not really be very surprising. In some studies
SIRT1 has been shown to interact with NFκB and to re-
press its activity by deacetylation [22,24]. But at present
little information is available on the molecular mecha-
nisms regulating the expression of SIRT1at the promoter
level. In the study presented herein, we show that in
addition to the already known regulation of NFκB by
SIRT1, NFκB overexpression enhances SIRT1 promoter ac-
tivity. Increased SIRT1 enzymatic activity caused by NFκB
overexpression was shown in a functional assay. The direct
binding of the transcription factor NFκB to the Sirt1oter. U937 cells were treated with TNFα to induce NFκB expression.
d with different biotin labeled DNA fragments of the SIRT1 promoter
cleotide was used as the positive control.
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shift assays. With these results a reciprocal feedback regula-
tion of SIRT1 at the promoter level through transcription
factor NFκB is shown to take place.
The conserved NFκB binding motif can be found three
times within the human SIRT1 promoter sequence. Dis-
tinguishing which of the three potential NFκB binding
sites was responsible for the activation of the promoter
could not be made since all of the created SIRT1 pro-
moter truncations showed binding of NFκB. With re-
porter plasmids containing the human SIRT1 promoter
sequence and luciferase assays, we were able to show
that high expression levels of NFκB subunits were able
to specifically activate SIRT1 at the promoter level. Our
experiments show that the NFκB binding motifs within
the SIRT1 promoter are functional, and that NFκB can
act as a positive regulator of SIRT1 at the promoter
level. In order to further examine whether NFκB over-
expression on SIRT1 promoter activation caused a real
increase in SIRT1 expression, we performed RT-PCR ex-
periments using cells overexpressing NFκB that showed
elevated levels of SIRT1 mRNA for most of the used
NFκB subunits. As a functional assay to measure SIRT1
activity the acetylation status of histone H4K16, which
is one of the most common targets of the deacetylase
SIRT1, was examined. The decrease in acetylation of
H4K16 under conditions of NFκB overexpression indi-
cates not only that SIRT1 protein levels are increased,
but also that this has measurable effects on downstream
targets. This means that at least some of the signaling
cascades and pathways that activate NFκB may influence
the expression of SIRT1 and the acetylation status of its
target proteins. The involvement of both of these pro-
teins in the development and progression of numerous
diseases such as cancer, arteriosclerosis or diabetes ren-
ders this regulation mechanism an interesting target for
further investigations with regard to the development of
novel molecular therapeutics affecting SIRT1 regulation.
SIRT1 is one of the most interesting targets for potential
epigenetic therapeutics and the ongoing attempts to cre-
ate specific activators or deactivators for SIRT1 may
benefit from better knowledge about its regulation by
intercellular transcription factors. Taken together, these
findings provide new insights into the regulation of
SIRT1 and interactions between NFκB and SIRT1. They
may promote a better understanding of the mechanism
involved in regulation of proteins that control proce-
dures as important as metabolism and aging.
Methods
Antibodies and plasmids
Anti-histone H4 monoclonal antibody (anti-H4) was pur-
chased from Abcam (Cambridge, UK) and antibody specific
for Histone H4 acetylated at lysine 16 (anti-H4K16) waspurchased from Upstate via Biomol, (Hamburg, Germany).
Secondary antibodies (anti-rabbit and anti-mouse horse-
radish peroxidase conjugates) were purchased from Santa
Cruz Biotechnology (Santa Cruz, California, USA).
NFκB expression plasmids for subunits p49, p50 and
p65 were based on pRSV expression vector systems and
were provided by the National Institutes of Health (NIH)
AIDS Research and Reference Reagent Program. For con-
struction of luciferase reporter plasmids, human SIRT1
promoter from genomic DNA was amplified by PCR. The
amplified region spanned the entire SIRT1 promoter re-
gion. The promoter was inserted into the luciferase re-
porter plasmid pGL2-basic, which was purchased from
Promega (Mannheim, Germany). All plasmids were propa-
gated using competent DH5α E. coli and were isolated
with a Nucleobond PC100 Kit from Macherey & Nagel
(Düren, Germany). All transfection experiments were car-
ried out in HEK293Tcells.
Luciferase reporter gene assays
HEK293T-cells were cultured in 12-well plates with DMEM
supplemented with 10% FCS and were cotransfected with
the luciferase SIRT1 promoter or empty pGL2basic vector
constructs and different combinations of expression vectors
encoding NFκB subunits. In order to normalize the total
amount of DNA that was used per transfection, empty vec-
tor was added in order to adjust the total amount of DNA.
Transfection was done using the nanoparticle-based trans-
fection reagent Nanofectin (PAA, Pasching, Austria) and
medium was changed 2 hours after transfection. Transfec-
tion efficiency was assessed by UV-microscopy after trans-
fection of green lantern constructs (Promega, Mannheim,
Germany). Cells were harvested after 24 hours and lucif-
erase activity was measured using the luciferase reporter
assay system (Promega, Mannheim, Germany) in accord-
ance with the manufacturer’s instructions. The activity of
each sample was normalized to its protein concentration
measured on a UV-Vis spectrophotometer Nanodrop™
ND1000 (PEQLAB, Erlangen, Germany) using DC Protein
assay (BioRad, Hercules, California, USA) based on the
Lowry method. Relative activity was calculated as fold dif-
ference in relation to the control vector pGL2basic. Lu-
ciferase assays were performed in duplicates and every
experiment was repeated at least twice.
Quantitative real-time PCR
Total RNA from HEK293T cells was extracted with the
Trifast reagent (Peqlab, Erlangen, Germany) in accordance
with the manufacturer’s instructions. Total RNA was
treated with Turbo DNAse (Life Technologies, Carlsbad,
USA) and was reverse transcribed with the High capacity
cDNA Reverse Transcription Kit from Applied Biosystems
(Darmstadt, Germany). The cDNA samples were ampli-
fied in quantitative real-time PCR using a Light Cycler
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Roche (Penzberg, Germany). The primers that were used
for amplification of human SIRT1 were as follows:
forward primer 5′- ACGCTGGAACAGGTTGCGGG
A - 3′,
reverse primer 5′- AAGCGGTTCATCAGCTGGGCA
C - 3′.
Thermal reaction cycles were as follows: initial cycle at
95°C for 10 min, which was then followed by 45 cycles
at 95°C for 10 sec, 60°C for 4 sec and 72°C for 16 sec.
GAPDH was used as an internal control to normalize
measured Ct values of each sample, and data were ana-
lyzed using the delta-delta Ct method.Extraction of histones and western blot
HEK293T cells were cultured in 12-well plates and were
harvested with 100 μl lysis buffer after incubation for 24
hours. While cells were being mixed vigorously, 25 μl of
2 M sulphuric acid were added drop by drop, and cells
were then placed on ice for 1 h. After centrifugation at
13,000 rpm, supernatants were collected, mixed with
400 μl of 20% trichloroacetic acid and incubated on ice
for histone precipitation. After 1 h the mixture was spun
down and the pellets containing histones were washed
twice with acidified acetone (0.1% HCl) and once with
pure acetone prior to resuspension in water. Extracted
histones were separated on a 15% polyacrylamide gel
and blotted onto a nitrocellulose membrane according
to the full-wet western blot technique. Acetylated his-
tones were detected with anti H4K16 antibody. For
detection, the ECL plus western blotting detection re-
agent from GE Healthcare (Little Chalfont, UK) was
used. After that, an antibody binding to H4 independ-
ent of the acetylation status was used in order to
detect total histone H4. Blots were scanned and quan-
tifications were calculated with the ImageQuant5.1 soft-
ware (GE Healthcare, Little Chalfont, UK). Signal of
acetylated H4 was normalized to the signal of total H4 in
order to eliminate effects depending on the western blot
technique itself.Table 1 Enzymes for digestion of SIRT1
promoter truncations
Fragment length Enzymes for plasmid digestion
2,228 bp Hind3
1,148 bp Bgl2 and Hind3
1,026 bp Kpn1 and Hind3
921 bp Sma1
887 bp Bgl2 and Hind3
668 bp Bgl2 and Hind3Promoter truncation and electrophoretic mobility shift
assay (EMSA)
The generation of the different promoter fragments was
done with different methods. The fragment with 921 bp
was generated by exonuclease digestion. Fragments with
1,148 bp and 1,026 bp were generated through restric-
tion enzyme digestion and subsequent re-ligation. Frag-
ments with 887 bp and 668 bp were amplified by PCR
from genomic DNA and inserted into an empty vector.
Plasmids were transformed into E. coli DH5a for propa-
gation and extracted accordingly. A total of 2 μg plasmid
DNA were digested with restriction enzymes (Table 1)
and then run on a 0.8% agarose gel. Digested fragments
from each construct were cut out while the gel was
monitored under UV control, and DNA elution was done
with a Silica Beads DNA gel extraction kit (Fermentas,
Waltham, USA). DNA from each construct was labeled
with biotin using the Biotin 3′ End DNA Labeling Kit
(Pierce Biotechnology, Waltham, USA). In order to stimu-
late NFκB expression, U937 cells were treated with re-
combinant TNFα at a concentration of 10 ng/ml for 30
minutes. Control cells were left untreated. Nuclear ex-
tracts (10 μg) were then incubated with a specific biotin-
labeled DNA sample before electrophoretic mobility shift
assay (EMSA) was done using a Light Shift Chemilumin-
escent EMSA kit (Pierce Biotechnology, Waltham, USA)
in accordance with the manufacturer’s instructions.
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